{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"retatrutide-chemo","title":"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals","body":"## What's breaking down\n\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\n\nPreclinical work in mouse models of pancreatic, lung, and breast cancer found tumor volume reductions with retatrutide, sometimes independent of weight loss and larger than semaglutide (preclinical|source s11, s16, s18). One model suggested it could sensitize triple-negative breast cancer cells to chemotherapy by affecting YAP pathways (preclinical|source s18). No human trials test retatrutide directly in chemo patients for tumor control or recovery.\n\n## Why Gabapentin / pregabalin matters for you\n\n1. Drug: Gabapentin / pregabalin\n2. What it does: Masks neuropathic pain signal; does not repair nerve.\n3. Therefore for you: This drug suppresses a signal. It can reduce perceived pain intensity in some neuropathic conditions but does not address underlying nerve damage or metabolic load. In chemo-induced peripheral neuropathy, evidence is limited and inconsistent; a 2024 meta-analysis found no significant benefit for prevention and mixed results for treatment (human|source s26, s27). It may trade off by allowing continued activity while symptoms persist, without supporting repair pathways.\n\n## How these fit together\n\nSingle-compound focus — Retatrutide targets metabolic load / body weight. Gabapentin/pregabalin addresses pain signaling separately. If your profile includes both weight-related mechanical stress and neuropathic signals, the two act on different layers without direct overlap. Weight reduction from retatrutide could indirectly lower overall stress on tissues already affected by neuropathy, but this remains untested in combined human studies.\n\n## What the evidence actually shows\n\nHuman trials: Large Phase 2 and 3 studies (thousands of participants) confirm dose-dependent weight loss of 17–30% over 48–104 weeks, plus improvements in HbA1c, lipids, and some pain scores in osteoarthritis subsets (human|source s22, s0, s4, s6). No dedicated trials in active chemotherapy or cancer survivors. Zero medullary thyroid cancer or C-cell hyperplasia cases reported in retatrutide trials to date (human|source s17).\n\nPreclinical: Mouse models of pancreatic ductal adenocarcinoma showed 14-fold tumor volume reduction with retatrutide vs 4-fold with semaglutide; lung models showed 17-fold reduction. Effects sometimes independent of weight loss (preclinical|source s11, s16). Breast cancer cell work indicated potential to overcome gemcitabine resistance (preclinical|source s18).\n\nAnecdotal: Limited Reddit discussions mention interest in metabolic effects post-cancer or concerns about prior cancer history; no consistent pattern of use or outcomes tied to chemo (anecdotal|source s30, s31, s34).\n\n## What scientists say\n\nResearchers note profound weight-loss effects comparable to bariatric surgery in some metrics, with cardiovascular risk marker improvements. Preclinical anti-tumor signals in specific models are described as independent of weight loss in some cases and warrant further study, but human translation is absent. Thyroid C-cell concerns stem from rodent data only; human trial monitoring has not shown signals (mechanistic/human|source s17, s16).\n\n## What people say on Reddit\n\nDiscussions center on general weight-loss potency versus other GLP-1 agents and occasional speculation about cancer-related metabolic benefits. Users with cancer history express caution about unapproved compounds. No detailed chemo-specific experience threads dominate (anecdotal|source s30, s31).\n\n## What people say on X\n\nPosts highlight trial weight-loss numbers and emerging preclinical cancer metabolism links. Some note anti-inflammatory observations in non-cancer contexts. No verified patient reports of chemo use appear in recent searches.\n\n## What we do not know\n\nNo human data exist on retatrutide safety, efficacy, or interactions during active chemotherapy, in cancer survivors, or combined with gabapentinoids for neuropathy. Long-term effects on muscle mass during chemo recovery, recurrence risk, or direct nerve repair remain unstudied. Preclinical tumor findings have not been replicated in humans.\n\n## Safety and limits\n\nRetatrutide remains investigational; Phase 3 trials continue with expected readouts through 2026–2027. Common side effects in trials include gastrointestinal issues typical of the class. Skin sensitivity was reported in 7% versus 1% placebo but was mild (human|source s22). Gabapentinoids carry dizziness, sedation, and dependence risks. Always consult oncology and prescribing teams; this is not guidance. Evidence inventory: human trials dominate weight-loss data (multiple large RCTs); preclinical cancer models are limited to mice; anecdotes are sparse and uncontrolled.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-chemo/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Phase 2 retatrutide trials showed up to 24% body weight loss at 48 weeks in adults with obesity.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s22"],"source_status":"sourced","why_material":"Establishes human weight-loss magnitude relevant to mechanical load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 TRIUMPH-1 showed 28.3% average weight loss at 80 weeks with 12 mg retatrutide.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s4","s0"],"source_status":"sourced","why_material":"Quantifies larger human effect size for load-related discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Mouse models showed 14-fold pancreatic tumor volume reduction with retatrutide vs 4-fold with semaglutide.","section":"Why Retatrutide might help you","tier":"preclinical","source_ids":["s11","s16"],"source_status":"sourced","why_material":"Documents specific preclinical cancer signal separate from weight loss.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"2024 meta-analysis found gabapentinoids do not significantly prevent CIPN and show inconsistent treatment effects.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s26","s27"],"source_status":"sourced","why_material":"Grades the signal-suppression evidence for neuropathy layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No medullary thyroid cancer cases reported in retatrutide Phase 2 trials of over 300 participants.","section":"What the evidence actually shows","tier":"human","source_ids":["s17"],"source_status":"sourced","why_material":"Clarifies human safety monitoring versus rodent signals.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks","summary":"Reports TRIUMPH-1 Phase 3 weight loss results.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"5ae26c8c70947e23ebb48cdbfd6bffe206bb08fc1869f9ca90552d60dbbc5f45"},{"id":"s4","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss","quote":"participants taking retatrutide 12 mg lost an average of 70.3 lbs (28.3%)","summary":"Official Lilly release on TRIUMPH-1 data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"5ae26c8c70947e23ebb48cdbfd6bffe206bb08fc1869f9ca90552d60dbbc5f45","hash":"7ae2b155cdd63d0a3cfc2aec3127bb336ce841169e0780fcb027fb23b7112e5f"},{"id":"s11","type":"pubmed","url":"https://jitc.bmj.com/content/13/Suppl_2/A752","title":"661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 in preclinical pancreatic cancer model","quote":"low-dose RETA significantly reduced tumor volume by 3-fold... comparable to anti-PD-1","summary":"Preclinical pancreatic cancer model results.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"7ae2b155cdd63d0a3cfc2aec3127bb336ce841169e0780fcb027fb23b7112e5f","hash":"fff9f7b520817158cd1d3cab9757904fc5bc4c894efccb9ba5086226905e9dfa"},{"id":"s16","type":"news","url":"https://conscienhealth.org/2025/03/19/an-effect-of-retatrutide-on-cancer-progression-in-mice/","title":"An Effect of Retatrutide on Cancer Progression in Mice?","quote":"reduced progression of pancreatic cancer yielded a striking 14-fold reduction in tumor volume","summary":"Summarizes mouse cancer model findings.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"fff9f7b520817158cd1d3cab9757904fc5bc4c894efccb9ba5086226905e9dfa","hash":"a59610332bc0a1f0e9a2d89d409b1a59b859663c6fdccf95368998736090c7e8"},{"id":"s17","type":"other","url":"https://www.redfoxpeptides.is/retatrutide-thyroid-cancer/","title":"Retatrutide and Thyroid Cancer: Why the Warning Exists","quote":"In Retatrutide Phase 2 clinical trials involving over 300 participants for 48 weeks, zero cases of medullary thyroid cancer or C-cell hyperplasia were reported.","summary":"Reviews thyroid safety data from trials.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"a59610332bc0a1f0e9a2d89d409b1a59b859663c6fdccf95368998736090c7e8","hash":"1ad3cde5f23e8fa5b06aa956880c9d4513230d1a983e1a32d879f49d2903dea3"},{"id":"s22","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.","summary":"NEJM Phase 2 publication on weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"1ad3cde5f23e8fa5b06aa956880c9d4513230d1a983e1a32d879f49d2903dea3","hash":"da5b16cc0660d5ba26abd8c0351bc4473ee846d196f350d797cfb85fee43b9c9"},{"id":"s26","type":"pubmed","url":"https://spcare.bmj.com/content/14/3/269","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","summary":"Meta-analysis on gabapentinoids for CIPN.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"da5b16cc0660d5ba26abd8c0351bc4473ee846d196f350d797cfb85fee43b9c9","hash":"11fb35829fb6fe1bdc0a9774e1a54c1ea9f8a854060beace21fb36578a8002ac"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"gabapentinoids do not significantly prevent CIPN","summary":"PubMed abstract of the meta-analysis.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"11fb35829fb6fe1bdc0a9774e1a54c1ea9f8a854060beace21fb36578a8002ac","hash":"4168f7f61c31cab053510c8658c8c2443e0d662d4e1a12c36a6739a976f2ff33"},{"id":"s30","type":"reddit","url":"https://www.reddit.com/r/RetatrutideGBP/comments/1o8q793/cancer_fight_why_some_studies_show_retatrutide/","title":"Cancer Fight? Why Some Studies Show Retatrutide Might Help","quote":"There's no evidence yet that Retatrutide should be used as a cancer therapy.","summary":"Reddit thread on preclinical cancer signals.","claim_ids":[],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"4168f7f61c31cab053510c8658c8c2443e0d662d4e1a12c36a6739a976f2ff33","hash":"fb4aed4a5ecb8a36bc6e7307de53cf6334bfb9f8470d34579ab3666786de40e1"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:03:29.547Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals","register":"source_ledger","body":"## What's breaking down\n\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\n\nPreclinical work in mouse models of pancreatic, lung, and breast cancer found tumor volume reductions with retatrutide, sometimes independent of weight loss and larger than semaglutide (preclinical|source s11, s16, s18). One model suggested it could sensitize triple-negative breast cancer cells to chemotherapy by affecting YAP pathways (preclinical|source s18). No human trials test retatrutide directly in chemo patients for tumor control or recovery.\n\n## Why Gabapentin / pregabalin matters for you\n\n1. Drug: Gabapentin / pregabalin\n2. What it does: Masks neuropathic pain signal; does not repair nerve.\n3. Therefore for you: This drug suppresses a signal. It can reduce perceived pain intensity in some neuropathic conditions but does not address underlying nerve damage or metabolic load. In chemo-induced peripheral neuropathy, evidence is limited and inconsistent; a 2024 meta-analysis found no significant benefit for prevention and mixed results for treatment (human|source s26, s27). It may trade off by allowing continued activity while symptoms persist, without supporting repair pathways.\n\n## How these fit together\n\nSingle-compound focus — Retatrutide targets metabolic load / body weight. Gabapentin/pregabalin addresses pain signaling separately. If your profile includes both weight-related mechanical stress and neuropathic signals, the two act on different layers without direct overlap. Weight reduction from retatrutide could indirectly lower overall stress on tissues already affected by neuropathy, but this remains untested in combined human studies.\n\n## What the evidence actually shows\n\nHuman trials: Large Phase 2 and 3 studies (thousands of participants) confirm dose-dependent weight loss of 17–30% over 48–104 weeks, plus improvements in HbA1c, lipids, and some pain scores in osteoarthritis subsets (human|source s22, s0, s4, s6). No dedicated trials in active chemotherapy or cancer survivors. Zero medullary thyroid cancer or C-cell hyperplasia cases reported in retatrutide trials to date (human|source s17).\n\nPreclinical: Mouse models of pancreatic ductal adenocarcinoma showed 14-fold tumor volume reduction with retatrutide vs 4-fold with semaglutide; lung models showed 17-fold reduction. Effects sometimes independent of weight loss (preclinical|source s11, s16). Breast cancer cell work indicated potential to overcome gemcitabine resistance (preclinical|source s18).\n\nAnecdotal: Limited Reddit discussions mention interest in metabolic effects post-cancer or concerns about prior cancer history; no consistent pattern of use or outcomes tied to chemo (anecdotal|source s30, s31, s34).\n\n## What scientists say\n\nResearchers note profound weight-loss effects comparable to bariatric surgery in some metrics, with cardiovascular risk marker improvements. Preclinical anti-tumor signals in specific models are described as independent of weight loss in some cases and warrant further study, but human translation is absent. Thyroid C-cell concerns stem from rodent data only; human trial monitoring has not shown signals (mechanistic/human|source s17, s16).\n\n## What people say on Reddit\n\nDiscussions center on general weight-loss potency versus other GLP-1 agents and occasional speculation about cancer-related metabolic benefits. Users with cancer history express caution about unapproved compounds. No detailed chemo-specific experience threads dominate (anecdotal|source s30, s31).\n\n## What people say on X\n\nPosts highlight trial weight-loss numbers and emerging preclinical cancer metabolism links. Some note anti-inflammatory observations in non-cancer contexts. No verified patient reports of chemo use appear in recent searches.\n\n## What we do not know\n\nNo human data exist on retatrutide safety, efficacy, or interactions during active chemotherapy, in cancer survivors, or combined with gabapentinoids for neuropathy. Long-term effects on muscle mass during chemo recovery, recurrence risk, or direct nerve repair remain unstudied. Preclinical tumor findings have not been replicated in humans.\n\n## Safety and limits\n\nRetatrutide remains investigational; Phase 3 trials continue with expected readouts through 2026–2027. Common side effects in trials include gastrointestinal issues typical of the class. Skin sensitivity was reported in 7% versus 1% placebo but was mild (human|source s22). Gabapentinoids carry dizziness, sedation, and dependence risks. Always consult oncology and prescribing teams; this is not guidance. Evidence inventory: human trials dominate weight-loss data (multiple large RCTs); preclinical cancer models are limited to mice; anecdotes are sparse and uncontrolled.","claims":[{"id":"c1","text":"Phase 2 retatrutide trials showed up to 24% body weight loss at 48 weeks in adults with obesity.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s22"],"source_status":"sourced","why_material":"Establishes human weight-loss magnitude relevant to mechanical load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 TRIUMPH-1 showed 28.3% average weight loss at 80 weeks with 12 mg retatrutide.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Quantifies larger human effect size for load-related discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Mouse models showed 14-fold pancreatic tumor volume reduction with retatrutide vs 4-fold with semaglutide.","section":"Why Retatrutide might help you","tier":"preclinical","source_ids":["s11","s16"],"source_status":"sourced","why_material":"Documents specific preclinical cancer signal separate from weight loss.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"2024 meta-analysis found gabapentinoids do not significantly prevent CIPN and show inconsistent treatment effects.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s26","s27"],"source_status":"sourced","why_material":"Grades the signal-suppression evidence for neuropathy layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No medullary thyroid cancer cases reported in retatrutide Phase 2 trials of over 300 participants.","section":"What the evidence actually shows","tier":"human","source_ids":["s17"],"source_status":"sourced","why_material":"Clarifies human safety monitoring versus rodent signals.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss","quote":"participants taking retatrutide 12 mg lost an average of 70.3 lbs (28.3%)","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"pubmed","url":"https://jitc.bmj.com/content/13/Suppl_2/A752","title":"661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 in preclinical pancreatic cancer model","quote":"low-dose RETA significantly reduced tumor volume by 3-fold... comparable to anti-PD-1","link_status":"http_403","quote_status":"unverified"},{"id":"s16","type":"news","url":"https://conscienhealth.org/2025/03/19/an-effect-of-retatrutide-on-cancer-progression-in-mice/","title":"An Effect of Retatrutide on Cancer Progression in Mice?","quote":"reduced progression of pancreatic cancer yielded a striking 14-fold reduction in tumor volume","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"other","url":"https://www.redfoxpeptides.is/retatrutide-thyroid-cancer/","title":"Retatrutide and Thyroid Cancer: Why the Warning Exists","quote":"In Retatrutide Phase 2 clinical trials involving over 300 participants for 48 weeks, zero cases of medullary thyroid cancer or C-cell hyperplasia were reported.","link_status":"ok","quote_status":"verified"},{"id":"s22","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.","link_status":"http_403","quote_status":"unverified"},{"id":"s26","type":"pubmed","url":"https://spcare.bmj.com/content/14/3/269","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","link_status":"http_403","quote_status":"unverified"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"gabapentinoids do not significantly prevent CIPN","link_status":"ok","quote_status":"verified"},{"id":"s30","type":"reddit","url":"https://www.reddit.com/r/RetatrutideGBP/comments/1o8q793/cancer_fight_why_some_studies_show_retatrutide/","title":"Cancer Fight? Why Some Studies Show Retatrutide Might Help","quote":"There's no evidence yet that Retatrutide should be used as a cancer therapy.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17480,"tokens_out":4119,"cost":0.0321475,"prev_hash":"genesis","hash":"a8911c46bca9e7d0ce8794834fd8c60878e0940375bc95d0a47a0495f8777978"}],"provenance":[{"ts":"2026-06-30T01:03:29.547Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Chemo\nSlug: retatrutide-chemo\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_","response":"{\n  \"slug\": \"retatrutide-chemo\",\n  \"title\": \"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals\",\n  \"body\": \"## What's breaking down\\n\\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\\n\\nPreclinical work in mouse models of pancreatic, lung, and breast cance","tokens_in":17480,"tokens_out":4119,"cost":0,"prev":"genesis","hash":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed"},{"ts":"2026-07-17T02:41:15.243Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-chemo","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed","hash":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"}],"energy":{"passes":2,"tokens_in":17480,"tokens_out":4119,"tokens_total":21599,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"},"posted_at":"2026-06-29T21:32:57.888Z","created_at":"2026-06-29T21:32:57.888Z","updated_at":"2026-07-17T02:41:15.243Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-chemo","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-chemo","json":"https://miscsubjects.com/api/articles/retatrutide-chemo","bundle":"https://miscsubjects.com/api/articles/retatrutide-chemo/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":9,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-chemo/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-chemo","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-chemo\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-chemo\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-chemo/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-chemo\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-chemo | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-chemo","json":"/api/articles/retatrutide-chemo","markdown":"/api/articles/retatrutide-chemo/bundle?format=markdown","skill":"/api/articles/retatrutide-chemo/skill","topology":"/api/articles/retatrutide-chemo/topology","versions":"/api/articles/retatrutide-chemo/revisions","invocations":"/api/articles/retatrutide-chemo/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-chemo","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"451142796ec4a590742d6e7ea5d6f7cf9f4bf6172cf321dc750e67c6fe3171ac","object":{"object_type":"article-object","identity":{"id":"article:retatrutide-chemo","slug":"retatrutide-chemo","title":"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/retatrutide-chemo","role":"explain","audience":"human"},"skill":{"route":"/api/articles/retatrutide-chemo/skill","role":"direct behavior","audience":"model","content":"---\nname: retatrutide-chemo\ndescription: Apply the Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals\n\nThis Skill is the behavioral expression of [the canonical article](/a/retatrutide-chemo). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/retatrutide-chemo.\n- Read claims and relationships at /api/articles/retatrutide-chemo/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Chemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while other\n\n## Representations\n\n- Human: /a/retatrutide-chemo\n- JSON: /api/articles/retatrutide-chemo\n- Relationships: /api/articles/retatrutide-chemo/topology\n- History: /api/articles/retatrutide-chemo/revisions\n"},"json":{"route":"/api/articles/retatrutide-chemo","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/retatrutide-chemo/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","retatrutide","chemo"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/retatrutide-chemo/invocations?status=success","failure_events":"/api/articles/retatrutide-chemo/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"retatrutide-chemo","title":"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals","body":"## What's breaking down\n\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\n\nPreclinical work in mouse models of pancreatic, lung, and breast cancer found tumor volume reductions with retatrutide, sometimes independent of weight loss and larger than semaglutide (preclinical|source s11, s16, s18). One model suggested it could sensitize triple-negative breast cancer cells to chemotherapy by affecting YAP pathways (preclinical|source s18). No human trials test retatrutide directly in chemo patients for tumor control or recovery.\n\n## Why Gabapentin / pregabalin matters for you\n\n1. Drug: Gabapentin / pregabalin\n2. What it does: Masks neuropathic pain signal; does not repair nerve.\n3. Therefore for you: This drug suppresses a signal. It can reduce perceived pain intensity in some neuropathic conditions but does not address underlying nerve damage or metabolic load. In chemo-induced peripheral neuropathy, evidence is limited and inconsistent; a 2024 meta-analysis found no significant benefit for prevention and mixed results for treatment (human|source s26, s27). It may trade off by allowing continued activity while symptoms persist, without supporting repair pathways.\n\n## How these fit together\n\nSingle-compound focus — Retatrutide targets metabolic load / body weight. Gabapentin/pregabalin addresses pain signaling separately. If your profile includes both weight-related mechanical stress and neuropathic signals, the two act on different layers without direct overlap. Weight reduction from retatrutide could indirectly lower overall stress on tissues already affected by neuropathy, but this remains untested in combined human studies.\n\n## What the evidence actually shows\n\nHuman trials: Large Phase 2 and 3 studies (thousands of participants) confirm dose-dependent weight loss of 17–30% over 48–104 weeks, plus improvements in HbA1c, lipids, and some pain scores in osteoarthritis subsets (human|source s22, s0, s4, s6). No dedicated trials in active chemotherapy or cancer survivors. Zero medullary thyroid cancer or C-cell hyperplasia cases reported in retatrutide trials to date (human|source s17).\n\nPreclinical: Mouse models of pancreatic ductal adenocarcinoma showed 14-fold tumor volume reduction with retatrutide vs 4-fold with semaglutide; lung models showed 17-fold reduction. Effects sometimes independent of weight loss (preclinical|source s11, s16). Breast cancer cell work indicated potential to overcome gemcitabine resistance (preclinical|source s18).\n\nAnecdotal: Limited Reddit discussions mention interest in metabolic effects post-cancer or concerns about prior cancer history; no consistent pattern of use or outcomes tied to chemo (anecdotal|source s30, s31, s34).\n\n## What scientists say\n\nResearchers note profound weight-loss effects comparable to bariatric surgery in some metrics, with cardiovascular risk marker improvements. Preclinical anti-tumor signals in specific models are described as independent of weight loss in some cases and warrant further study, but human translation is absent. Thyroid C-cell concerns stem from rodent data only; human trial monitoring has not shown signals (mechanistic/human|source s17, s16).\n\n## What people say on Reddit\n\nDiscussions center on general weight-loss potency versus other GLP-1 agents and occasional speculation about cancer-related metabolic benefits. Users with cancer history express caution about unapproved compounds. No detailed chemo-specific experience threads dominate (anecdotal|source s30, s31).\n\n## What people say on X\n\nPosts highlight trial weight-loss numbers and emerging preclinical cancer metabolism links. Some note anti-inflammatory observations in non-cancer contexts. No verified patient reports of chemo use appear in recent searches.\n\n## What we do not know\n\nNo human data exist on retatrutide safety, efficacy, or interactions during active chemotherapy, in cancer survivors, or combined with gabapentinoids for neuropathy. Long-term effects on muscle mass during chemo recovery, recurrence risk, or direct nerve repair remain unstudied. Preclinical tumor findings have not been replicated in humans.\n\n## Safety and limits\n\nRetatrutide remains investigational; Phase 3 trials continue with expected readouts through 2026–2027. Common side effects in trials include gastrointestinal issues typical of the class. Skin sensitivity was reported in 7% versus 1% placebo but was mild (human|source s22). Gabapentinoids carry dizziness, sedation, and dependence risks. Always consult oncology and prescribing teams; this is not guidance. Evidence inventory: human trials dominate weight-loss data (multiple large RCTs); preclinical cancer models are limited to mice; anecdotes are sparse and uncontrolled.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/retatrutide-chemo/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"Phase 2 retatrutide trials showed up to 24% body weight loss at 48 weeks in adults with obesity.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s22"],"source_status":"sourced","why_material":"Establishes human weight-loss magnitude relevant to mechanical load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 TRIUMPH-1 showed 28.3% average weight loss at 80 weeks with 12 mg retatrutide.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s4","s0"],"source_status":"sourced","why_material":"Quantifies larger human effect size for load-related discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Mouse models showed 14-fold pancreatic tumor volume reduction with retatrutide vs 4-fold with semaglutide.","section":"Why Retatrutide might help you","tier":"preclinical","source_ids":["s11","s16"],"source_status":"sourced","why_material":"Documents specific preclinical cancer signal separate from weight loss.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"2024 meta-analysis found gabapentinoids do not significantly prevent CIPN and show inconsistent treatment effects.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s26","s27"],"source_status":"sourced","why_material":"Grades the signal-suppression evidence for neuropathy layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No medullary thyroid cancer cases reported in retatrutide Phase 2 trials of over 300 participants.","section":"What the evidence actually shows","tier":"human","source_ids":["s17"],"source_status":"sourced","why_material":"Clarifies human safety monitoring versus rodent signals.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks","summary":"Reports TRIUMPH-1 Phase 3 weight loss results.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"5ae26c8c70947e23ebb48cdbfd6bffe206bb08fc1869f9ca90552d60dbbc5f45"},{"id":"s4","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss","quote":"participants taking retatrutide 12 mg lost an average of 70.3 lbs (28.3%)","summary":"Official Lilly release on TRIUMPH-1 data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"5ae26c8c70947e23ebb48cdbfd6bffe206bb08fc1869f9ca90552d60dbbc5f45","hash":"7ae2b155cdd63d0a3cfc2aec3127bb336ce841169e0780fcb027fb23b7112e5f"},{"id":"s11","type":"pubmed","url":"https://jitc.bmj.com/content/13/Suppl_2/A752","title":"661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 in preclinical pancreatic cancer model","quote":"low-dose RETA significantly reduced tumor volume by 3-fold... comparable to anti-PD-1","summary":"Preclinical pancreatic cancer model results.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"7ae2b155cdd63d0a3cfc2aec3127bb336ce841169e0780fcb027fb23b7112e5f","hash":"fff9f7b520817158cd1d3cab9757904fc5bc4c894efccb9ba5086226905e9dfa"},{"id":"s16","type":"news","url":"https://conscienhealth.org/2025/03/19/an-effect-of-retatrutide-on-cancer-progression-in-mice/","title":"An Effect of Retatrutide on Cancer Progression in Mice?","quote":"reduced progression of pancreatic cancer yielded a striking 14-fold reduction in tumor volume","summary":"Summarizes mouse cancer model findings.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"fff9f7b520817158cd1d3cab9757904fc5bc4c894efccb9ba5086226905e9dfa","hash":"a59610332bc0a1f0e9a2d89d409b1a59b859663c6fdccf95368998736090c7e8"},{"id":"s17","type":"other","url":"https://www.redfoxpeptides.is/retatrutide-thyroid-cancer/","title":"Retatrutide and Thyroid Cancer: Why the Warning Exists","quote":"In Retatrutide Phase 2 clinical trials involving over 300 participants for 48 weeks, zero cases of medullary thyroid cancer or C-cell hyperplasia were reported.","summary":"Reviews thyroid safety data from trials.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"a59610332bc0a1f0e9a2d89d409b1a59b859663c6fdccf95368998736090c7e8","hash":"1ad3cde5f23e8fa5b06aa956880c9d4513230d1a983e1a32d879f49d2903dea3"},{"id":"s22","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.","summary":"NEJM Phase 2 publication on weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"1ad3cde5f23e8fa5b06aa956880c9d4513230d1a983e1a32d879f49d2903dea3","hash":"da5b16cc0660d5ba26abd8c0351bc4473ee846d196f350d797cfb85fee43b9c9"},{"id":"s26","type":"pubmed","url":"https://spcare.bmj.com/content/14/3/269","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","summary":"Meta-analysis on gabapentinoids for CIPN.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"http_403","quote_status":"unverified","prev":"da5b16cc0660d5ba26abd8c0351bc4473ee846d196f350d797cfb85fee43b9c9","hash":"11fb35829fb6fe1bdc0a9774e1a54c1ea9f8a854060beace21fb36578a8002ac"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"gabapentinoids do not significantly prevent CIPN","summary":"PubMed abstract of the meta-analysis.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"verified","prev":"11fb35829fb6fe1bdc0a9774e1a54c1ea9f8a854060beace21fb36578a8002ac","hash":"4168f7f61c31cab053510c8658c8c2443e0d662d4e1a12c36a6739a976f2ff33"},{"id":"s30","type":"reddit","url":"https://www.reddit.com/r/RetatrutideGBP/comments/1o8q793/cancer_fight_why_some_studies_show_retatrutide/","title":"Cancer Fight? Why Some Studies Show Retatrutide Might Help","quote":"There's no evidence yet that Retatrutide should be used as a cancer therapy.","summary":"Reddit thread on preclinical cancer signals.","claim_ids":[],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:03:17.837Z","link_status":"ok","quote_status":"unverified","prev":"4168f7f61c31cab053510c8658c8c2443e0d662d4e1a12c36a6739a976f2ff33","hash":"fb4aed4a5ecb8a36bc6e7307de53cf6334bfb9f8470d34579ab3666786de40e1"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-30T01:03:29.547Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals","register":"source_ledger","body":"## What's breaking down\n\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\n\n## Why Retatrutide might help you\n\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\n\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\n\nPreclinical work in mouse models of pancreatic, lung, and breast cancer found tumor volume reductions with retatrutide, sometimes independent of weight loss and larger than semaglutide (preclinical|source s11, s16, s18). One model suggested it could sensitize triple-negative breast cancer cells to chemotherapy by affecting YAP pathways (preclinical|source s18). No human trials test retatrutide directly in chemo patients for tumor control or recovery.\n\n## Why Gabapentin / pregabalin matters for you\n\n1. Drug: Gabapentin / pregabalin\n2. What it does: Masks neuropathic pain signal; does not repair nerve.\n3. Therefore for you: This drug suppresses a signal. It can reduce perceived pain intensity in some neuropathic conditions but does not address underlying nerve damage or metabolic load. In chemo-induced peripheral neuropathy, evidence is limited and inconsistent; a 2024 meta-analysis found no significant benefit for prevention and mixed results for treatment (human|source s26, s27). It may trade off by allowing continued activity while symptoms persist, without supporting repair pathways.\n\n## How these fit together\n\nSingle-compound focus — Retatrutide targets metabolic load / body weight. Gabapentin/pregabalin addresses pain signaling separately. If your profile includes both weight-related mechanical stress and neuropathic signals, the two act on different layers without direct overlap. Weight reduction from retatrutide could indirectly lower overall stress on tissues already affected by neuropathy, but this remains untested in combined human studies.\n\n## What the evidence actually shows\n\nHuman trials: Large Phase 2 and 3 studies (thousands of participants) confirm dose-dependent weight loss of 17–30% over 48–104 weeks, plus improvements in HbA1c, lipids, and some pain scores in osteoarthritis subsets (human|source s22, s0, s4, s6). No dedicated trials in active chemotherapy or cancer survivors. Zero medullary thyroid cancer or C-cell hyperplasia cases reported in retatrutide trials to date (human|source s17).\n\nPreclinical: Mouse models of pancreatic ductal adenocarcinoma showed 14-fold tumor volume reduction with retatrutide vs 4-fold with semaglutide; lung models showed 17-fold reduction. Effects sometimes independent of weight loss (preclinical|source s11, s16). Breast cancer cell work indicated potential to overcome gemcitabine resistance (preclinical|source s18).\n\nAnecdotal: Limited Reddit discussions mention interest in metabolic effects post-cancer or concerns about prior cancer history; no consistent pattern of use or outcomes tied to chemo (anecdotal|source s30, s31, s34).\n\n## What scientists say\n\nResearchers note profound weight-loss effects comparable to bariatric surgery in some metrics, with cardiovascular risk marker improvements. Preclinical anti-tumor signals in specific models are described as independent of weight loss in some cases and warrant further study, but human translation is absent. Thyroid C-cell concerns stem from rodent data only; human trial monitoring has not shown signals (mechanistic/human|source s17, s16).\n\n## What people say on Reddit\n\nDiscussions center on general weight-loss potency versus other GLP-1 agents and occasional speculation about cancer-related metabolic benefits. Users with cancer history express caution about unapproved compounds. No detailed chemo-specific experience threads dominate (anecdotal|source s30, s31).\n\n## What people say on X\n\nPosts highlight trial weight-loss numbers and emerging preclinical cancer metabolism links. Some note anti-inflammatory observations in non-cancer contexts. No verified patient reports of chemo use appear in recent searches.\n\n## What we do not know\n\nNo human data exist on retatrutide safety, efficacy, or interactions during active chemotherapy, in cancer survivors, or combined with gabapentinoids for neuropathy. Long-term effects on muscle mass during chemo recovery, recurrence risk, or direct nerve repair remain unstudied. Preclinical tumor findings have not been replicated in humans.\n\n## Safety and limits\n\nRetatrutide remains investigational; Phase 3 trials continue with expected readouts through 2026–2027. Common side effects in trials include gastrointestinal issues typical of the class. Skin sensitivity was reported in 7% versus 1% placebo but was mild (human|source s22). Gabapentinoids carry dizziness, sedation, and dependence risks. Always consult oncology and prescribing teams; this is not guidance. Evidence inventory: human trials dominate weight-loss data (multiple large RCTs); preclinical cancer models are limited to mice; anecdotes are sparse and uncontrolled.","claims":[{"id":"c1","text":"Phase 2 retatrutide trials showed up to 24% body weight loss at 48 weeks in adults with obesity.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s22"],"source_status":"sourced","why_material":"Establishes human weight-loss magnitude relevant to mechanical load reduction.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Phase 3 TRIUMPH-1 showed 28.3% average weight loss at 80 weeks with 12 mg retatrutide.","section":"Why Retatrutide might help you","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Quantifies larger human effect size for load-related discussion.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Mouse models showed 14-fold pancreatic tumor volume reduction with retatrutide vs 4-fold with semaglutide.","section":"Why Retatrutide might help you","tier":"preclinical","source_ids":["s11","s16"],"source_status":"sourced","why_material":"Documents specific preclinical cancer signal separate from weight loss.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"2024 meta-analysis found gabapentinoids do not significantly prevent CIPN and show inconsistent treatment effects.","section":"Why Gabapentin / pregabalin matters for you","tier":"human","source_ids":["s26","s27"],"source_status":"sourced","why_material":"Grades the signal-suppression evidence for neuropathy layer.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"No medullary thyroid cancer cases reported in retatrutide Phase 2 trials of over 300 participants.","section":"What the evidence actually shows","tier":"human","source_ids":["s17"],"source_status":"sourced","why_material":"Clarifies human safety monitoring versus rodent signals.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-30T01:03:28.309Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s0","type":"news","url":"https://pharmaceutical-journal.com/article/news/phase-iii-retatrutide-study-demonstrates-30-weight-loss","title":"Phase III retatrutide study demonstrates 30% weight loss","quote":"participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss","quote":"participants taking retatrutide 12 mg lost an average of 70.3 lbs (28.3%)","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"pubmed","url":"https://jitc.bmj.com/content/13/Suppl_2/A752","title":"661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 in preclinical pancreatic cancer model","quote":"low-dose RETA significantly reduced tumor volume by 3-fold... comparable to anti-PD-1","link_status":"http_403","quote_status":"unverified"},{"id":"s16","type":"news","url":"https://conscienhealth.org/2025/03/19/an-effect-of-retatrutide-on-cancer-progression-in-mice/","title":"An Effect of Retatrutide on Cancer Progression in Mice?","quote":"reduced progression of pancreatic cancer yielded a striking 14-fold reduction in tumor volume","link_status":"ok","quote_status":"verified"},{"id":"s17","type":"other","url":"https://www.redfoxpeptides.is/retatrutide-thyroid-cancer/","title":"Retatrutide and Thyroid Cancer: Why the Warning Exists","quote":"In Retatrutide Phase 2 clinical trials involving over 300 participants for 48 weeks, zero cases of medullary thyroid cancer or C-cell hyperplasia were reported.","link_status":"ok","quote_status":"verified"},{"id":"s22","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight.","link_status":"http_403","quote_status":"unverified"},{"id":"s26","type":"pubmed","url":"https://spcare.bmj.com/content/14/3/269","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"There is limited evidence to support the use of gabapentinoids in CIPN.","link_status":"http_403","quote_status":"unverified"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38936970/","title":"Gabapentinoids for chemotherapy-induced peripheral neuropathy","quote":"gabapentinoids do not significantly prevent CIPN","link_status":"ok","quote_status":"verified"},{"id":"s30","type":"reddit","url":"https://www.reddit.com/r/RetatrutideGBP/comments/1o8q793/cancer_fight_why_some_studies_show_retatrutide/","title":"Cancer Fight? Why Some Studies Show Retatrutide Might Help","quote":"There's no evidence yet that Retatrutide should be used as a cancer therapy.","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":17480,"tokens_out":4119,"cost":0.0321475,"prev_hash":"genesis","hash":"a8911c46bca9e7d0ce8794834fd8c60878e0940375bc95d0a47a0495f8777978"}],"provenance":[{"ts":"2026-06-30T01:03:29.547Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Retatrutide for Chemo\nSlug: retatrutide-chemo\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"retatrutide\",\"name\":\"Retatrutide\"}],\"drugs_in_scope\":[\"gabapentin-lyrica\"],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"retatrutide\",\"name\":\"Retatrutide\",\"section_title\":\"Why Retatrutide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\",\"**What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\",\"**Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.\\n2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.\\n3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_","response":"{\n  \"slug\": \"retatrutide-chemo\",\n  \"title\": \"Retatrutide for Chemo: Evidence on Metabolic Load, Weight, and Related Signals\",\n  \"body\": \"## What's breaking down\\n\\nChemotherapy can trigger several layers of change. One common layer is shifts in body weight and metabolic state — some regimens promote weight gain through fluid retention, reduced activity, or steroid use, while others lead to loss. Excess weight multiplies compressive forces on the spine, hips, knees, and other structures (roughly 4 lb of lumbar load per extra pound of body weight). Another layer is neuropathic pain signals from nerve irritation, often addressed with medications like gabapentin or pregabalin. A third layer involves systemic inflammation and insulin signaling that may interact with recovery. These layers do not all repair at once; addressing one (such as load) can change the environment for the others. Retatrutide is studied mainly for the metabolic and weight layer. Gabapentin/pregabalin targets the pain-signal layer.\\n\\n## Why Retatrutide might help you\\n\\n1. What keeps failing: Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia. During or after chemo, weight changes can add to this mechanical stress.\\n2. What Retatrutide is studied to do: Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration or nerve repair.\\n3. Therefore for you: If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\\n\\nHuman data show substantial weight reduction. In Phase 2 trials, participants lost up to 24% body weight at 48 weeks (human|source s22). Phase 3 TRIUMPH-1 results at 80 weeks reached 28.3% average loss at 12 mg, with some reaching 30% at longer follow-up (human|source s4, s0). These changes reduce overall body mass and associated compressive forces.\\n\\nPreclinical work in mouse models of pancreatic, lung, and breast cance","tokens_in":17480,"tokens_out":4119,"cost":0,"prev":"genesis","hash":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed"},{"ts":"2026-07-17T02:41:15.243Z","model":"owner","action":"voxel_divide","prompt":"","input":"retatrutide-chemo","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f30cc0c3762379285ce9f3b772c4cf0b120725f543b546c05409098193ea65ed","hash":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"}],"energy":{"passes":2,"tokens_in":17480,"tokens_out":4119,"tokens_total":21599,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"34034dce22ce2f1521de7ba42763ea12ec8db0a98dbac93e3f3ff6e3bd08636b"},"posted_at":"2026-06-29T21:32:57.888Z","created_at":"2026-06-29T21:32:57.888Z","updated_at":"2026-07-17T02:41:15.243Z","machine":{"shape":"article.machine/v1","slug":"retatrutide-chemo","kind":"article","read":{"human":"https://miscsubjects.com/a/retatrutide-chemo","json":"https://miscsubjects.com/api/articles/retatrutide-chemo","bundle":"https://miscsubjects.com/api/articles/retatrutide-chemo/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":5,"sources":9,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/retatrutide-chemo/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=retatrutide-chemo","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-chemo\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"retatrutide-chemo\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/retatrutide-chemo/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"retatrutide-chemo\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/retatrutide-chemo | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/retatrutide-chemo","json":"/api/articles/retatrutide-chemo","markdown":"/api/articles/retatrutide-chemo/bundle?format=markdown","skill":"/api/articles/retatrutide-chemo/skill","topology":"/api/articles/retatrutide-chemo/topology","versions":"/api/articles/retatrutide-chemo/revisions","invocations":"/api/articles/retatrutide-chemo/invocations"},"editorial_review":null,"editorial_audit":{"slug":"retatrutide-chemo","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"451142796ec4a590742d6e7ea5d6f7cf9f4bf6172cf321dc750e67c6fe3171ac"}}}